M Untch Selected Research

M Untch Research Topics

Disease

61	Breast Neoplasms (Breast Cancer) 04/2024 - 01/2000
37	Neoplasms (Cancer) 01/2021 - 01/2000
11	Triple Negative Breast Neoplasms 04/2024 - 12/2013
7	Neoplasm Metastasis (Metastasis) 03/2016 - 01/2000
3	Residual Neoplasm 02/2024 - 06/2001
3	Thrombocytopenia (Thrombopenia) 01/2021 - 02/2011
2	Diarrhea 11/2016 - 02/2011
2	Disease Progression 04/2015 - 06/2001
2	Sarcoma (Soft Tissue Sarcoma) 02/2015 - 04/2006
2	Carcinoma (Carcinomatosis) 03/2014 - 06/2001
2	Cardiotoxicity 05/2004 - 09/2000
2	Ovarian Neoplasms (Ovarian Cancer) 06/2001 - 05/2000
1	Second Primary Neoplasms (Neoplasms, Second) 01/2022
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2021
1	Hemorrhage 01/2021
1	Pathologic Complete Response 01/2017
1	Febrile Neutropenia 11/2016
1	Dizziness (Lightheadedness) 11/2016
1	Myoma 02/2015
1	Leiomyoma (Uterine Fibroids) 02/2015
1	Hiatal Hernia 08/2013
1	Airway Obstruction (Choking) 08/2013
1	Inflammatory Breast Neoplasms 08/2012
1	Infections 02/2011
1	Leukopenia 02/2011
1	Hyperlipidemias (Hyperlipidemia) 02/2011
1	Edema (Dropsy) 02/2011
1	Mucositis 02/2011
1	Cardiovascular Diseases (Cardiovascular Disease) 02/2011
1	Hypertension (High Blood Pressure) 02/2011

Drug/Important Bio-Agent (IBA)

19	Trastuzumab (Herceptin)FDA Link 01/2021 - 09/2000
18	Epirubicin (Ellence)FDA LinkGeneric 11/2022 - 01/2000
15	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2022 - 05/2000
12	taxaneIBA 07/2022 - 09/2007
11	AnthracyclinesIBA 07/2022 - 12/2004
9	Paclitaxel (Taxol)FDA LinkGeneric 04/2024 - 05/2000
7	Hormones (Hormone)IBA 01/2021 - 04/2002
6	Biomarkers (Surrogate Marker)IBA 07/2022 - 04/2002
6	Plasminogen Activator Inhibitor 1IBA 05/2013 - 01/2000
6	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 05/2013 - 01/2000
5	human ERBB2 proteinIBA 04/2024 - 06/2008
5	Lapatinib (GW572016)FDA Link 01/2019 - 02/2011
5	AntibodiesIBA 09/2007 - 01/2001
4	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 05/2000
4	Proteins (Proteins, Gene)FDA Link 01/2015 - 09/2000
4	Docetaxel (Taxotere)FDA Link 12/2014 - 02/2011
4	Fluorouracil (Carac)FDA LinkGeneric 09/2007 - 09/2000
4	Plasminogen InactivatorsIBA 08/2001 - 01/2000
3	Immune Checkpoint InhibitorsIBA 11/2022 - 01/2019
3	durvalumabIBA 11/2022 - 01/2019
3	Bevacizumab (Avastin)FDA Link 12/2014 - 02/2011
3	Methotrexate (Mexate)FDA LinkGeneric 09/2001 - 09/2000
3	Drug CombinationsIBA 09/2001 - 05/2000
2	130-nm albumin-bound paclitaxelIBA 11/2022 - 01/2017
2	ParaffinIBA 12/2018 - 01/2001
2	Diphosphonates (Bisphosphonates)IBA 03/2016 - 01/2016
2	Zoledronic Acid (Zometa)FDA Link 03/2016 - 01/2016
2	Everolimus FDA Link 12/2014 - 02/2011
2	Plasminogen Activators (Plasminogen Activator)IBA 05/2013 - 04/2006
2	Darbepoetin alfa (Aranesp)FDA Link 09/2011 - 09/2011
2	Vinorelbine (Navelbine)FDA LinkGeneric 10/2006 - 06/2001
2	Tissue ExtractsIBA 04/2006 - 08/2001
2	Adenosine Triphosphate (ATP)IBA 06/2001 - 05/2000
1	cabazitaxel FDA Link 04/2024
1	Phenobarbital (Luminal)FDA Link 04/2024
1	pembrolizumabIBA 02/2024
1	veliparibIBA 01/2022
1	Immunoconjugates (Immunoconjugate)IBA 01/2022
1	trastuzumab deruxtecanIBA 01/2022
1	Ado-Trastuzumab EmtansineIBA 01/2021
1	PlatinumIBA 01/2021
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	olaparibIBA 01/2021
1	MutagensIBA 01/2021
1	Indicators and Reagents (Reagents)IBA 01/2021
1	Formaldehyde (Formol)FDA Link 12/2018
1	Estrogen ReceptorsIBA 12/2018
1	pertuzumabIBA 01/2017
1	SolventsIBA 01/2017
1	CreatinineIBA 11/2016
1	Clodronic Acid (Clodronate)IBA 03/2016
1	N,N'-bis(4-azidobenzoyl)cystineIBA 02/2016
1	Biosimilar PharmaceuticalsIBA 04/2015
1	HematinicsIBA 04/2015
1	Cysteine (L-Cysteine)FDA Link 01/2015
1	Capecitabine (Xeloda)FDA Link 01/2014
1	Messenger RNA (mRNA)IBA 03/2013
1	Growth Factor ReceptorsIBA 02/2011
1	bis(beta-carboxyethyl)tin dichlorideIBA 09/2007
1	Antineoplastic Agents (Antineoplastics)IBA 05/2007

Therapy/Procedure

36	Drug Therapy (Chemotherapy) 02/2024 - 01/2000
26	Therapeutics 01/2021 - 01/2000
22	Neoadjuvant Therapy 04/2024 - 06/2001
3	Adjuvant Chemotherapy 01/2019 - 01/2000
3	Hysterectomy 02/2015 - 04/2006
2	Cesarean Section (Caesarean Section) 03/2014 - 06/2004
1	Duration of Therapy 11/2022
1	Morcellation 02/2015
1	Operative Surgical Procedures 02/2015
1	Ex utero Intrapartum Treatment Procedures 08/2013